Sector News

Deal-talkers J&J, Actelion reportedly land on a price, but spinoff details still pending

January 13, 2017
Life sciences

Johnson & Johnson and Actelion are working out a deal that would send the Swiss biotech’s marketed meds to New Jersey.

Johnson & Johnson and Actelion may have finally settled a key condition of their long-discussed transaction.

The pair has landed on a price for the deal, Bloomberg reports, although sources didn’t tell the news service what that price was. Reuters reported earlier this month that J&J was considering a price in the $260-per-share range for Actelion’s marketed meds, a figure that would bring the buy to more than $28 billion.

Now, word has it the companies are hammering out valuations for Actelion’s R&D assets, which would reportedly be spun off into a new company as part of any acquisition. Which products specifically would go into that unit and how much ownership Actelion’s investors would keep are both under negotiation, but sources say the companies could strike a pact as early as this month.

J&J’s courtship of the Swiss biotech has been a long one, in part thanks to Actelion founder and CEO Jean-Paul Clozel’s desire to keep a piece of his company flying solo. Earlier talks hit a snag in December when the pair quit talking—only to restart a week later and force Sanofi, which had entered after J&J threw in the towel, out of the picture.

New Jersey-based J&J, which is seeking revenue growth now that a biosimilar competitor to top med Remicade has arrived in the U.S., has been more or less amenable to Clozel’s desires, though working out the complex deal structure has been slow going.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend